PharmSource: Contract Manufacturing of Novel In-Licensed Drugs - 2020 Edition
NEW YORK, March 27, 2020 /PRNewswire/ --
PharmSource: Contract Manufacturing of Novel In-Licensed Drugs - 2020 Edition
Read the full report: https://www.reportlinker.com/p05878094/?utm_source=PRN
Summary
This expert trend report explores in-licensing trends among FDA New Molecule Entity (NME) approvals 2014-2018, and analyzes how licensing patterns affect propensity to outsource finished dose manufacture. This report is critical for establishing an understanding of the ways bio/pharmaceutical companies source their drugs, and the factor that make them more likely to engage a contract manufacturing organization (CMO).
Scope
- CMO executives who must have a deep understanding of the NME approvals landscape to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Pharmaceutical and biotech companies evaluating potential licensing deals as a licensor or licensee.
- Investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
- Overview of novel drugs (NMEs) approved by FDA 2014-2018
- Detailed analysis of dose outsourcing likelihood by: licensing status, market cap, molecule type
- Spotlight on licensing deals and outsourcing propensity
- Detailed methodology explains use of data from the Pharma Intelligence Center databases
Read the full report: https://www.reportlinker.com/p05878094/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article